Search results
Results from the WOW.Com Content Network
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ginkgo Bioworks wasn’t one of them. The 10 stocks that made ...
Ginkgo Bioworks has become a penny stock -- and that's the least of its problems, Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst Skip to main content
It has been difficult to be a shareholder of Ginkgo Bioworks (NYSE: DNA) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell engineering foundry is ...
For premium support please call: 800-290-4726 more ways to reach us
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $3.12, marking a -0.32% move from the previous day.
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology .
[3] [4] The diversity of Ginkgoales declined during the Late Cretaceous and Cenozoic, coincident with the rise of flowering plants, with all Ginkgophytes aside from Ginkgo being extinct by the end of the Cretaceous. [5] [4] The only remaining Ginkgophyte was Ginkgo adiantoides – a polymorphic species. [6] Modern Ginkgo trees are native to ...
For premium support please call: 800-290-4726 more ways to reach us